<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03094351</url>
  </required_header>
  <id_info>
    <org_study_id>RAE20170320</org_study_id>
    <nct_id>NCT03094351</nct_id>
  </id_info>
  <brief_title>Robot Assisted Thoraco-Laparoscopic Esophagectomy Versus Conventional Thoraco-Laparoscopic Esophagectomy</brief_title>
  <acronym>RATLE vs CTLE</acronym>
  <official_title>Robot Assisted Thoraco-laparoscopic Esophagectomy Versus Conventional Thoraco-laparoscopic Esophagectomy for Patients With Squamous Cell Esophageal Cancer: a Multicenter Open-label, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Chest Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first randomized controlled study to compare the robot-assisted
      thoraco-laparoscopic esophagectomy (RATLE) to minimally invasive conventional
      thoraco-laparoscopic esophagectomy (CTLE). The aim of this trial is to evaluate the safety,
      risks of the robot-assisted esophagectomy, and to compare the short-term operative outcomes
      and long-term oncological outcomes between the two surgical treatments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: This study aims to compare the oncological outcomes between robot-assisted
      thoraco-laparoscopic esophagectomy and minimally invasive conventional thoraco-laparoscopic
      esophagectomy.

      Study design: Randomized controlled parallel-group superiority trial Study population:
      Patients (age &gt;= 18 and &lt;= 75 years) with histologically proven surgically resectable
      (cT1b-3, N0-2, M0) squamous cell carcinoma of the intrathoracic esophagus with European
      Clinical Oncology Group performance status 0, 1 or 2.

      Intervention: 300 patients will be randomly allocated to either A) robot-assisted
      thoraco-laparoscopic esophagectomy (n=150) or B) conventional thoraco-laparoscopic
      esophagectomy (n=150).

      Patients will receive the following interventions:

      Group A. robot assisted thoraco-laparoscopic esophagectomy, with gastric conduit formation.

      Group B. conventional thoraco-laparoscopic esophagectomy, with gastric conduit formation.

      Main study parameters/endpoints: Primary outcome is 5-year overall survival rate.

      Secondary outcomes are 5-year disease free survival, 3-year overall survival rate, 3-year
      disease free survival, (in hospital) mortality within 30 and 60 days, R0 resections,
      operation related events, postoperative recovery, lymph nodes status, quality of life.

      Follow-up: 60 months after discharge of the last randomized patient.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival Rate</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>R0 resection (%)</measure>
    <time_frame>within 30 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival Rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative major complications</measure>
    <time_frame>30 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In hospital mortality</measure>
    <time_frame>30-60 days after surgery</time_frame>
    <description>For all patients, the cause of death will be noted. If applicable, the results of the autopsy report will be noted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative duration</measure>
    <time_frame>during the operation, up to 5 hours</time_frame>
    <description>The operation time is defined as time from incision until closure (minutes) for both the thoracic phase and the abdominal phase of the procedure. For the robotic procedure, the set-up time will be recorded separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative recovery</measure>
    <time_frame>from the date of surgery to the hospital discharge, assessed up to 15 days</time_frame>
    <description>Postoperative hospital stay, intensive care unit (ICU) stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of lymph nodes dissected</measure>
    <time_frame>within 30 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>2 years</time_frame>
    <description>The quality of life assessment was based on a previously validated questionnaire, QLQ-C30 (version 3.0; quality-of-life questionnaire), combined with an esophageal cancer-specific module, QLQ-OES18.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated blood loss</measure>
    <time_frame>during the operation, up to 5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival Rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Esophageal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Robot assisted esophagectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Robot-assisted thoraco-laparoscopic esophagectomy with gastric conduit formation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thoraco-laparoscopic esophagectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional thoraco-laparoscopic esophagectomy with gastric conduit formation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>esophagectomy</intervention_name>
    <description>Robot assisted thoraco-laparoscopic esophagectomy with extended two field lymphadenectomy.</description>
    <arm_group_label>Robot assisted esophagectomy</arm_group_label>
    <other_name>minimally invasive esophagectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>esophagectomy</intervention_name>
    <description>Conventional thoraco-laparoscopic esophagectomy with extended two field lymphadenectomy.</description>
    <arm_group_label>Thoraco-laparoscopic esophagectomy</arm_group_label>
    <other_name>minimally invasive esophagectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven squamous cell carcinoma of the intrathoracic esophagus.

          -  Surgical resectable (T1b-3, N0-2, M0)

          -  Age ≥ 18 and ≤ 75 years

          -  European Clinical Oncology Group performance status 0, 1 or 2

          -  Written informed consent

        Exclusion Criteria:

          -  Carcinoma of the cervical esophagus

          -  Histologically proven adenocarcinoma or undifferentiated carcinoma.

          -  Prior thoracic surgery at the right hemithorax or thorax trauma.

          -  Infectious disease with systemic therapy indicated.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhigang Li, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Chest Hospital, Shanghai Jiao Tong University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hecheng Li, Master</last_name>
    <role>Study Director</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hezhong Chen, Master</last_name>
    <role>Study Director</role>
    <affiliation>Changhai Hospital, The Second Military Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lijie Tan, Master</last_name>
    <role>Study Director</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhigang Li, Master</last_name>
    <phone>86-18930619260</phone>
    <email>zhigang.li@shchest.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaobin Zhang, Doctor</last_name>
    <phone>86-18516302162</phone>
    <email>zxb5212@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Changhai Hospital, The Second Military Medical University</name>
      <address>
        <city>Shanghai</city>
        <zip>021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hezhong Chen</last_name>
      <phone>86-13301783183</phone>
      <email>drchenhz@citiz.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hecheng Li, Master</last_name>
      <phone>86-13917113402</phone>
      <email>lihecheng2000@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lijie Tan, Master</last_name>
      <phone>86-13681972151</phone>
      <email>tan.lijie@zs-hospital.sh.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital, Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhigang Li, Master</last_name>
      <phone>86-18930619260</phone>
      <email>zhigang.li@shchest.org</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2017</study_first_submitted>
  <study_first_submitted_qc>March 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2017</study_first_posted>
  <last_update_submitted>July 29, 2017</last_update_submitted>
  <last_update_submitted_qc>July 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Chest Hospital</investigator_affiliation>
    <investigator_full_name>Zhiang Li</investigator_full_name>
    <investigator_title>Chief</investigator_title>
  </responsible_party>
  <keyword>robot assisted esophagectomy</keyword>
  <keyword>minimally invasive esophagectomy</keyword>
  <keyword>esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

